Roche scores CE mark for molecular Dx systems; Quest's Focus Diagnostics wins FDA nod for additional flu strains;

> Roche ($RHHBY) won a CE mark for its Cobas HIV-1 and HCV molecular diagnostic systems. Story (reg. req.)

> Quest Diagnostics' ($DGX) Focus Diagnostics scored FDA clearance for eight additional flu strains in its Simplexa Flu molecular diagnostic kit. More (reg. req.)

> Foundation Medicine ($FMI) revealed new data showing that 68% of patients who underwent treatment based on results from its FoundationOne Heme genomic profile experienced clinical benefit. Release

> The Broad Institute granted GE Healthcare ($GE) and Sigma-Aldrich ($SIAL) non-exclusive licenses to intellectual property including patents for gene-editing technology. More (reg. req.)

> The FDA approved a labeling update for NanoString Technologies' Prosigna breast cancer assay which provides additional information about risk of recurrence following diagnosis. Story (reg. req.)

> Paris-based Novacyt raised €3.1 million ($3.8 million) in private equity placement to beef up sales in emerging markets and develop infectious disease diagnostics. Story (reg. req.)

> Kapa Biosystems is kicking off a new direct sales model in the U.K., expanding the market for its PCR, qPCR, next-generation sequencing and molecular diagnostics. More (reg. req.)

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.